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C-reactive proteinAbstract Pleural effusion is relatively common clinical condition that requires differential diagno-
sis. It is deﬁned as collection of ﬂuid in pleural space. Pleural effusion is often diagnostic dilemma
for the physician.
The aim of the study was to assess the procalcitonin (PCT) and C-reactive protein (CRP) levels in
serum and pleural ﬂuid to evaluate their usefulness in the differentiation among benign and malig-
nant pleural effusions.
This study was conducted in Chest Department, Tanta University Hospital, it included 54 adult
patients with pleural effusions of different etiologies, 8 transudative effusion, 14 para-pneumonic
effusion, 14 tuberculous effusion and 18 malignant effusion. We measured serum and pleural pro-
calcitonin and C-reactive protein by ELISA.
The mean serum and pleural ﬂuid procalcitonin (PCT) levels in parapneumonic effusions were
signiﬁcantly higher compared with transudative, tuberculous and malignant pleural effusions
p< 0.05. A signiﬁcant positive correlation between serum and pleural ﬂuid PCT levels was
observed in the studied groups. The mean serum and pleural ﬂuid CRP concentration were signif-
icantly lower in malignant and transudative pleural effusion than tuberculous and para-pneumonic
effusion p< 0.05.
Signiﬁcant positive correlation between serum and pleural ﬂuid CRP levels was observed in the
studied groups. Procalcitonin levels in serum and pleural effusion were signiﬁcantly lower in malig-
nant effusion compared to para-pneumonic pleural effusion and CRP levels were signiﬁcantly lower
compared to other types of exudative pleural effusion.
ª 2014 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis. Open access under CC BY-NC-ND license.
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Pleural effusion is relatively common clinical condition that
requires differential diagnosis. Pleural effusion is often diag-
nostic dilemma for the physician as the differential diagnosis
is wide [1].
It may represent the primary manifestation of certain dis-
eases, however, it is commonly observed as a secondary man-
ifestation or complication of other diseases such as
pneumonia, malignancy, pulmonary embolism, gastrointesti-
nal diseases which account for at least 90% of all exudative
pleural effusion [2].
Classiﬁcation of pleural effusion into transudative and exu-
dative is currently based on Light’s criteria [1]. In order to
achieve a speciﬁc diagnosis especially in exudative effusion sev-
eral biomarkers have been applied to permit rapid and accu-
rate diagnosis as conventional methods are not always able
to establish the cause. These biomarkers such as procalcitonin
and C-reactive protein (CRP) are used in several studies [3–5].
Among the potentially available laboratory parameters,
procalcitonin (PCT) has recently become of interest as a possi-
ble marker of the systemic inﬂammatory response to infection
[3]. It is normally produced in the C-cells of the thyroid gland
and is the precursor of calcitonin. A speciﬁc protease cleaves
PCT to calcitonin, Katacalcin, and an N-terminal residue.
Normally, PCT is cleaved and none is released into the blood
stream such that levels are undetectable (<0.1 ng/mL) in
healthy humans. In severe bacterial infections and sepsis, how-
ever, intact PCT is found in blood. PCT levels increase in
response to a stimulus within 2–6 h. A half-life of approxi-
mately 20–24 h. is expected for PCT after a single, acute stim-
ulus. Unlike most cytokines, PCT is highly stable in collected
blood samples. Thus, it has been described as a good predictor
of disease severity and antibiotic efﬁciency [5].
C-reactive protein (CRP) is an acute phase protein synthe-
sized mainly by hepatocytes in response to tissue injury or
inﬂammation [4–7].
Malignancy is a common and important cause of exudative
pleural effusions in Egypt. Because pleural ﬂuid cytology and
pleural biopsy specimens do not provide a diagnosis in a high
percentage of malignant effusions, several tumor markers have
been studied. To overcome this limitation, several authors
hypothesized that measurement of procalcitonin and C-reac-
tive protein (CRP) would be useful in differentiating between
transudates and exudates besides between benign and malig-
nant effusion [6–8].
Aim of the work
The aim of the study was to assess the procalcitonin and C-
reactive protein levels in serum and pleural ﬂuid to evaluate
their usefulness in the differentiation among benign and malig-
nant pleural effusions.Patients and method
This study was conducted in Chest Department Tanta Univer-
sity Hospital, it included 54 adult patients with pleural
effusions of different etiologies. The study protocol wasapproved by Ethics Committee Faculty of Medicine Tanta
University.
These patients were classiﬁed according to their ﬁnal diag-
nosis into 4 groups:
Group I: 8 patients with Transudative pleural effusion.
Group II: 14 patients with para-pneumonic pleural effusion.
Group III: 14 patients with tuberculous pleural effusion.
Group IV: 18 patients with malignant pleural effusion.
Patients were subjected to:
1. Full medical history and clinical examination.
2. Routine laboratory investigations e.g.: blood urea and
serum creatinine, Liver function especially albumin, Colla-
gen proﬁle as needed.
3. Radiological examination:
– Plain chest X-ray postro-anterior and lateral views.
– Whenever needed the following is done:h CT scan of the chest.
h Abdominal ultrasonography.
h Echocardiography.
4. Tuberculin test.
5. Sputum examination for: acid fast, alcohol fast bacilli
(AFB) by Ziehl–Neelsen stain on 3 successive days.
6. Sputum cytology was done for detection of malignant and/
or inﬂammatory cells.
7. Diagnostic thoracocentesis.
– Collection and processing of the pleural ﬂuid samples
(about 300–500 ml) were done and subjected to the fol-
lowing examinations:
h Physical examination.
h Chemical examination including: protein level, LDH
level, total and differential cell count and adenosine
deaminase level when tuberculous effusion is
suspected.
h Bacteriological examination.
h Cytological examination for malignant cells.
h Quantitative measurement of pleural ﬂuid procalcito-
nin and CRP.
8. Collection of 3 ml of venous blood for quantitative mea-
surement of serum procalcitonin and CRP.
There is no risk or complications happened to the patients
during the period of research, and all patients gave their
informed written consents.
Diagnostic criteria for pleural effusions
Pleural effusion was classiﬁed into transudates and exudates
according to Light’s criteria. An exudative pleural effusion
was deﬁned by one or more of following:
Ratio of lactate dehydrogenase, (LDH) in the pleural ﬂuid
to that in the plasma of more than 0.6.
Ratio of total protein in the pleural ﬂuid to that in the
plasma of more than 0.5.
Total pleural ﬂuid protein more than 3 gm%.
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sion was accompanied by community-acquired pneumonia,
but the effusion was not grossly purulent, no bacteria were
detected on the Gram stain, and culture of the pleural ﬂuid
was negative for bacteria.
Tuberculous pleuritis was deﬁned as one or more of the fol-
lowing criteria:
Mycobacteria or caseating granuloma detected on patho-
logical examination of pleural biopsy.
Elevated adenosine deaminase (ADA) level in pleural ﬂuid,
tuberculin test was positive and both clinical and radiological
response to anti-tuberculous treatment were evident.
Malignant pleural effusion was deﬁned as malignant cells
detected on cytological examination of the effusion or pleural
biopsy and no evidence of obstructive pneumonia.
Exclusion criteria:
1. Patient under chemo or radiotherapy.
2. Patient with empyema.
3. Immunocompromised patients.
4. Pregnant women.
5. Contraindication for thoracocentesis e.g. patient is con-
fused or bad general condition.
6. Inadequate amount of effusion drained for diagnostic
procedures.
Measurement of procalcitonin
The PCT concentrations in serum and pleural ﬂuid were deter-
mined using an enzyme linked immunosorbent assay (ELISA).
The test required 2–3 h and only 20 lL of serum or pleural
ﬂuid. The microtiter plate provided in this kit has been coated
with monoclonal antibodies speciﬁc to PCT. Standards or
samples were then added to microtiter plate wells with a bio-
tin-conjugated polyclonal antibody preparation speciﬁc to
PCT. Next, Avidin conjugated to Horseradish Peroxidase
(HRP) was added to each microplate well and incubated. Then
a tetramethylbenzidine (TMB) substrate solution was added to
each well. Only those wells that contain PCT, biotin-conju-
gated antibody and enzyme-conjugated Avidin exhibited
change in color.
The enzyme-substrate reaction was terminated by the addi-
tion of sulfuric acid solution and color changes were measured
spectrophotometrically at wavelength 450 nm± 10 nm. The
PCT in the samples was then determined by comparing the
optical density of the samples to the standard curve.
Measurement of C-reactive protein
The CRP concentrations in serum and pleural ﬂuid were deter-
mined using a high sensitivity enzyme linked immunosorbent
assay (ELISA) which based on the principle of a solid phase
enzyme linked immunosorbent assay. The assay system utilizes
a unique monoclonal antibodies directed against distinct anti-
genic determinant on the CRP molecule. This mouse monoclo-
nal anti-CRP antibody was used for solid phase
immobilization (on the microtiter wells). A goat anti-CRP
antibody is an antibody – enzyme (Horseradish peroxidase)
conjugate solution. The test sample was allowed to react simul-
taneously with the two antibodies, resulting in the CRPmolecules being sandwiched between two antibodies. After a
45-minute incubation at room temperature, the wells were
washed with water to remove unbound labeled antibodies. A
tetramethylbenzidine (TMB) reagent was added and incubated
for 20 min, resulting in development of blue color. The color
development was stopped with addition of 1 N HCl changing
the color to yellow. The concentration of CRP is directly pro-
portional the color intensity of the test sample. Absorbance is
measured spectrophotometrically at 450 nm.
Statistics
Statistical presentation and analysis of the present study were
conducted, using the mean standard deviation, by SPSS V.16.
Analysis of variance (ANOVA) test was used for compari-
son among different groups and Linear Correlation Coefﬁcient
(r) was used to correlate serum and pleural ﬂuid levels in dif-
ferent groups.Results
This study included 54 adult patients with pleural effusions of
different etiologies.
These patients were classiﬁed according to their ﬁnal diag-
nosis into 4 groups:
Group I: 8 patients with Transudative pleural effusions, (5
males and 3 females). 6 hepatic patients, 1cardiac patient
and 1 renal patient.
Hepatic effusions (3 males and 3 females) were massive Rt.
Sided effusion with manifestation of hepatic insufﬁciency such
as jaundice, massive ascites, L.L. edema with impairment of
liver functions.
Cardiac effusion (1 male patient) has Rt. Sided moderate
pleural effusion with echocardiography ejection fraction 28%.
Renal effusion (1 male patient) has bilateral moderate pleu-
ral effusion with elevated serum creatinine and blood urea and
was on regular hemodialysis.
Group II: 14 patients with para-pneumonic pleural effu-
sions (11 males and 3 females), were presented by high grade
fever, cough and expectoration of purulent sputum with mild
to moderate pleural effusion. All were neutrophilic exudates.
Improvement occurred after administration of combined anti-
biotics for at least two weeks.
Group III: 14 patients with Tuberculous pleural effusions,
(12 males and 2 females) were presented by T.B. toxemia (loss
of weight, loss of appetite, night sweating night fever) with
mild to moderate pleural effusion. The effusion was lympho-
cytic exudates.
Z.N. stain for sputum was ve for acid fast bacilli in all
patients, tuberculin test was +ve in 12 patients, adenosine
deaminase (ADA) was +ve (more than 40 IU/L) in 10 cases,
2 cases are diagnosed by thoracoscopic biopsy (characteristic
caseating granuloma of T.B). Improvement occurred after ini-
tial course of antituberculous drugs in combination with
corticosteroids.
Group IV: 18 patients with malignant pleural effusions, (8
males and 10 females) have moderate to massive pleural
effusion.
6 patients (4 males and 2 females) with malignant effusions
were diagnosed by +ve malignant cytology in pleural ﬂuid.
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nosed by +ve malignant cytology in pleural ﬂuid.
3 patients (2 males and 1 female) with metastatic broncho-
genic carcinoma were diagnosed by bronchoscopic biopsy.
1 female patient with mantle cell lymphoma presented by
generalized lymphadenopathy with hepato-splenomegaly and
diagnosed by +ve malignant lymphocytic cells in pleural ﬂuid
and with histopathological examination of excisional lymph
node biopsy.
1 male patient with malignant mesothelioma was diagnosed
by thoracoscopic biopsy.
3 patients (1 male and 2 females) with metastatic adenocar-
cinoma were diagnosed by thoracoscopic biopsy.
1 female patient with metastatic anaplastic carcinoma from
malignant eye tumor was diagnosed by thoracoscopic biopsy.
1 female patient with metastatic malignant hamartoma
from Rt. sided ovarian malignant hamartoma.Procalcitonin level in serum (Fig. 1)
Procalcitonin (PCT) levels of serum ranged from 0.05–
0.38 ng/ml with mean value (0.155 ± 0.038 ng/ml) in
transudative effusion, and ranged from 0.69–4.32 ng/ml
with mean (2.171 ± 0.341 ng/ml) in para-pneumonic effu-
sion, and ranged from 0.01–0.27 ng/ml with mean
(0.265 ± 0.152 ng/ml) in tuberculous effusion, and ranged
from 0.13–2.3 ng/ml with mean (0.965 ± 0.164 ng/ml) in
malignant effusion.
Analysis of variance (ANOVA) test showed signiﬁcant sta-
tistical difference as regards serum procalcitonin levels in the
four studied groups (F= 18.117, p< 0.001).
Repeated measures analysis of variance showed that serum
procalcitonin level was signiﬁcantly higher in para-pneumonic
effusion as compared with transudative, tuberculous, and
malignant effusion.
Serum procalcitonin level was signiﬁcantly higher in
patients with para-pneumonic effusion (2.171 ± 0.341 ng/ml)
as compared with those with malignant effusion
(0.965 ± 0.164 ng/ml) p< 0.001, also, serum procalcitonin
level was signiﬁcantly higher in patients with malignant
effusion (0.965 ± 0.164 ng/ml) as compared with those with
transudative effusion (0.155 ± 0.038) p< 0.001 and tubercu-
lous pleural effusion (0.265 ± 0.152 ng/ml) p< 0.05.0.155
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Figure 1 Serum and pleural ﬂuid procalcProcalcitonin level in pleural effusion (Fig. 1)
Procalcitonin levels of pleural ﬂuid ranged from 0.07–0.27 ng/
ml with mean (0.169 ± 0.074 ng/ml) in transudative effusion,
and ranged from 0.55–3.97 ng/ml with mean (1.760 ± 0.312
ng/ml) in para-pneumonic effusion, and ranged from 0.04–
0.5 ng/ml with mean (0.204 ± 0.033 ng/ml) in tuberculous
effusion, and ranged from 0.06–2.22 ng/ml with mean
(0.636 ± 0.167 ng/ml) in malignant effusion.
One way analysis of variance (ANOVA) of pleural ﬂuid
procalcitonin levels in 4 studied groups showed signiﬁcant sta-
tistical difference (F= 13.440, p< 0.001).
Repeated measures analysis of variance showed that pleural
ﬂuid procalcitonin level was signiﬁcantly higher in patients
with para-pneumonic effusion as compared with transudative,
tuberculous, and malignant effusions.
Pleural ﬂuid procalcitonin level was signiﬁcantly higher in
patients with para-pneumonic effusion (1.760 ± 0.312 ng/ml)
as compared with those with malignant effusion (0.636 ±
0.167 ng/ml) p< 0.05.
Pleural ﬂuid procalcitonin level was signiﬁcantly higher in
patients with malignant effusion (0.636 ± 0.167 ng/ml) as
compared with those with transudative effusion (0.169 ±
0.074 ng/ml) p< 0.001 and tuberculous pleural effusion
(0.204 ± 0.033 ng/ml) p< 0.05.Correlation between procalcitonin level in serum and pleural
ﬂuid
Signiﬁcantly positive correlation was found between the serum
and pleural ﬂuid procalcitonin levels among patients in the
four studied groups (r= 0.905 p< 0.001) (Fig. 2).C-reactive protein (CRP) level in serum (Fig. 3)
CRP levels of serum ranged from 3.2–7.5 mg/dl with mean
value (4.975 ± 1.263 mg/dl) in transudative effusion, & ranged
from 6.9–24 mg/dl with mean (12.439 ± 5.850 mg/dl) in para-
pneumonic effusion, ranged from 8.5–21 mg/dl with mean
(14.110 ± 3.62 mg/dl) in tuberculous effusion, and ranged
from 3.5–10 mg/dl with mean (6.450 ± 2.240 mg/dl) in malig-
nant effusion.0.265
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Figure 2 Correlation between serum and pleural effusion procalcitonin level in para-pneumonic effusion group.
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els showed signiﬁcant statistical difference between 4 studied
groups (F= 17.296 p= 0.001).
Repeated measures analysis of variance showed that serum
CRP level was signiﬁcantly higher in patients with tuberculous
effusion as compared with transudative, para-pneumonic, and
malignant effusions.
Serum CRP level was signiﬁcantly higher in patient with
tuberculous effusion (14.110 ± 3.62 mg/dl) as compared with
malignant effusion (6.450 ± 2.240 mg/dl) p< 0.001.
Serum CRP level was signiﬁcantly higher in patient
with para-pneumonic effusion (12.439 ± 5.850 mg/dl) as com-
paredwithmalignant effusion (6.450 ± 2.240 mg/dl)p< 0.001.4.975
12.439
1.113
6.865
0 
2 
4 
6 
8 
10
12
14
16
Transudave eﬀusion Parapneumonic 
eﬀusion
CR
P 
le
ve
l (
m
g/
dl
).
Serum CRP
Figure 3 Serum and pleural ﬂuid CR
-5 
0 
5 
10
15
20
25
5 7 9 11 13 1Pl
eu
ra
l e
ﬀ
us
io
n 
CR
P 
Le
ve
l (
m
g/
dl
) 
Serum CRP 
Figure 4 Correlation between serum and pleuralNo signiﬁcant difference was found in serum CRP level in
patient with malignant effusion (6.450 ± 2.240 mg/dl) as com-
pared with transudative effusion (4.975 ± 1.263 mg/dl)
p= 0.069.C-reactive protein (CRP) level in pleural effusion (Fig. 3)
CRP levels of pleural ﬂuid ranged from 0.4–2 mg/dl and the
mean value was (1.113 ± 0.574 mg/dl) in transudative
effusion, and ranged from 1.8–20.8 mg/dl with mean
(6.865 ± 1.658 mg/dl) in para-pneumonic effusion, and ranged
from 2.1–16 mg/dl with mean (6.992 ± 3.727 mg/dl) in14.11
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P levels in the four studied groups.
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928 W.S. El-Shimy et al.tuberculous effusion, and ranged from 1.01–6.8 mg/dl with
mean (2.491 ± 1.69 mg/dl) in malignant effusion.
One way analysis of variance (ANOVA) of pleural ﬂuid
CRP levels showed signiﬁcant statistical difference between 4
studied groups (F= 7.196 p= 0.002) .
Repeated measures analysis of variance showed that pleural
ﬂuid CRP level was signiﬁcantly higher in patients with tuber-
culous effusion as compared with transudative, para-pneu-
monic, and malignant effusion.
Pleural ﬂuid CRP level was signiﬁcantly lower in patient
with malignant effusion (2.491 ± 1.69 mg/dl) as compared
with para-pneumonic effusion (6.865 ± 1.658 mg/dl) and in
patient with tuberculous effusion (6.992 ± 3.727 mg/dl)
p= 0.003 and 0.002 respectively.
No signiﬁcant difference was found in pleural ﬂuid CRP
levels in patient with malignant effusion (2.491 ± 1.69 mg/dl)
as compared with transudative effusion (1.113 ± 0.574 mg/dl)
p= 0.159.
Correlation between CRP level in serum and pleural ﬂuid
There were signiﬁcantly positive correlations between serum
and pleural ﬂuid levels of CRP in the 4 studied groups
(r= 0.863 p< 0.001) (Fig. 4).Discussion
According to the present study procalcitonin was useful in dis-
criminating para-pneumonic effusion from other groups, this
was attributed to fact that it increases in systemic
inﬂammation.
This ﬁnding was in agree with Sang et al. [6], who assessed
procalcitonin and C-reactive protein (CRP) in pleural effu-
sions and serum to determine if they can differentiate an exu-
date from transudate as well as the diverse causes of exudative
pleural effusion. Their study was carried on 178 patients with
pleural effusion (malignant 57, tuberculous 51, para-pneu-
monic 31, empyema 5, miscellaneous benign 7 transudative
27). They found that serum and pleural procalcitonin and
CRP levels in the exudates were signiﬁcantly higher than those
in the transudate. Also, the serum and pleural procalcitonin
and CRP levels in the benign effusion were signiﬁcantly higher
than those in the malignant effusion. The pleural procalcitonin
levels in the non-tuberculous effusion were signiﬁcantly higher
than those in the tuberculous effusion.
They concluded that, measuring the level of procalcitonin
and CRP in the serum and pleural ﬂuid is helpful for differen-
tiating between transudates and exudates. In addition, it is use-
ful for differentiating between benign and malignant pleural
effusions [6].
In other study done by Ko et al. [9] assessed serum and
pleural ﬂuid procalcitonin in predicting bacterial infection in
patients with para-pneumonic effusion. Their study was car-
ried on 41 patients (35 males and 15 females) with a median
age of 67 yr. Of these, 25 had bacterial para-pneumonic effu-
sion (PPE) and 16 had non-bacterial para-pneumonic effusion.
The median PCT levels in pleural ﬂuid were signiﬁcantly
higher in the bacterial PPE than in the non-bacterial PPE,
but no statistical difference for serum PCT. They concluded
that, the pleural ﬂuid PCT levels in bacterial PPE are signiﬁ-
cantly different from those of the non-bacterial PPE.Lin et al. [10] showed the diagnostic and prognostic values
of pleural ﬂuid procalcitonin in para-pneumonic pleural effu-
sions. Their study was carried on 82 adult patients with pleural
effusions which was divided into the following two groups: the
para-pneumonic pleural effusion group (n= 45); and the non-
para-pneumonic pleural effusion group (n= 37). Levels of
pleural ﬂuid (PF) PCT and serum (S) PCT were determined
in all patients after study enrollment as well as on day 3 only
in the para-pneumonic pleural effusion group. They found
that, PF-PCT and S-PCT levels were signiﬁcantly higher in
PPPEs group than the non-PPPEs group. They concluded
that, PF-PCT and S-PCT are useful in the severity assessment
of patients with PPPEs. The PF-PCT/S-PCT ratio may help to
predict prolonged chest tube drainage.
Also, Wang et al. [11] determined the diagnostic value of
procalcitonin (PCT) in the differentiation of infectious and
noninfectious causes of pleural effusion. The PCT, LDH, total
protein, and CRP levels were measured in pleural effusions,
WBCs were counted in pleural effusion and whole blood sam-
ples, and CRP levels were also measured in sera from 76
patients. The types of pleural effusions studied were para-
pneumonic effusion (n= 26), empyema (n= 7), tuberculous
pleurisy (n= 8), malignant pleural effusion (n= 25) and
transudative pleural effusion (n= 8). They found that, PCT
levels were low in transudative pleural effusions and tubercu-
lous pleurisy, but high in empyema, para-pneumonic effusion,
and malignant pleural effusion. Also, the mean PCT level for
malignant effusion was signiﬁcantly higher than for tubercu-
lous pleurisy.
To differentiate between malignant effusions and tubercu-
lous pleurisy, the tuberculous pleurisy had higher levels of effu-
sion LDH, effusion total proteins, effusion WBC, effusion
CRP, and even serum CRP. Therefore, tuberculous pleurisy
should be highly suspected, when pleural effusion had a lower
level of PCT and higher levels of LDH, total protein, WBC or
CRP [11].
However, Cakir et al. [12] investigated the use of pleural
ﬂuid and serum procalcitonin as diagnostic tools in tubercu-
lous pleurisy. A prospective clinical study was performed
with two different patient groups. A total of 28 patients
were included: 18 with tuberculosis and 10 with non-tuber-
culous pleurisy. Serum and pleural ﬂuid PCT concentrations
were evaluated and were statistically different between tuber-
culous and d 10 with non-t pleurisy groups. They concluded
that, PCT concentration is not a useful parameter for the
diagnosis of tuberculous pleurisy because the PCT levels in
patients with tuberculous pleurisy were below the current
cut-off level of 0.5 ng/mL. The use of PCT should be further
investigated.
Pisani et al. [13] studied procalcitonin and CRP in pleural
effusion. Their study was carried on 43 patients with exudative
pleural effusions (24 of inﬂammatory origin and 19 of malig-
nant origin) and 7 patients with transudative pleural effusions
due to congestive heart failure. The aim of their study was to
compare the serum and pleural ﬂuid concentrations of PCT
and CRP in order to predict the inﬂammatory or malignant
origin of pleural effusions of unknown origin. Pleural ﬂuid
CRP and PCT concentrations were higher in exudative than
transudative effusions. Within the exudates CRP levels were
higher in the group of inﬂammatory effusions compared to
the group of malignant effusions. They concluded that, CRP
is important to discriminate inﬂammatory from malignant
Diagnostic value of procalcitonin and C-reactive protein effusions 929effusions. Moreover, although serum PCT concentration is a
sensitive and speciﬁc biomarker of systemic bacterial infection
they did not found statistically signiﬁcant differences in PCT
levels between inﬂammatory and malignant effusions. There-
fore, the role and the usefulness of assessment of PCT levels
in pleural ﬂuid diagnosis is far to be elucidated.
Porcel et al. [14] assessed some biomarkers of infection for
differential diagnosis of pleural effusion. Their study was car-
ried out on 308 patients with different causes of pleural effu-
sion. They aimed to investigate whether pleural ﬂuid
concentrations of biomarkers for bacterial infection, namely
triggering receptor expressed on myeloid cells (sTREM-1),
procalcitonin (PCT), lipopolysaccharide-binding protein
(LBP) and C-reactive protein (CRP), might identify infectious
effusions and discriminate between complicated para-pneu-
monic effusions (CPPEs) and uncomplicated para-pneumonic
effusions (UPPEs). Median pleural ﬂuid levels of CRP,
sTREM-1 and LBP were signiﬁcantly higher in CPPE com-
pared with those in other etiologies.
They concluded that, elevated pleural ﬂuid levels of CRP,
sTREM and LBP identify patients with infectious effusions,
particularly those with CPPE while PCT has no value for the
differential diagnosis of pleural effusions.
Wang et al. [11] determined the diagnostic value of procalc-
itonin (PCT) in the differentiation of infectious and noninfec-
tious causes of pleural effusion. Signiﬁcant correlation was
found between pleural effusion PCT and serum PCT levels
in 16 patients: 12 patients with para-pneumonic effusions
and the other 4 with malignant effusions. Also, Cakir et al.
[12] investigated the use of pleural ﬂuid and serum procalcito-
nin as diagnostic tools in tuberculous pleurisy. They found
positive and signiﬁcant correlation between serum and pleural
ﬂuid PCT levels in tuberculous group.
CRP is an acute phase reactant widely used as a marker of
inﬂammation and tissue injury. The present study showed that,
the mean serum and pleural ﬂuid CRP concentration were low
in transudative and malignant effusion and high in para-pneu-
monic and tuberculous effusions. They were signiﬁcantly
higher in tuberculous effusion than transudative, para-pneu-
monic and malignant effusions.
The mean serum and pleural ﬂuid CRP concentration were
signiﬁcantly lower in malignant effusion than tuberculous
effusion.
These results are in agreement with Daniil et al. [15] they
studied the use of pleural ﬂuid C-reactive protein in laboratory
diagnosis of pleural effusions. The aim of their study was to
investigate its usefulness as a marker of bacterial infection in
patients with pleural effusion. Their study was carried out on
72 patients with pleural effusion, 19 patients with transudates
had signiﬁcantly lower CRP level than those in the exudate
effusions group. Among the 53 patients with exudates effusion,
8 were caused by neoplastic diseases, they were signiﬁcantly
lower than those in exudates from para-pneumonic effusions
and then patients with effusion associated with tuberculosis.
They concluded that, higher pleural ﬂuid CRP-levels may
prove to be a practical, accurate and rapid method for differ-
entiating para-pneumonic effusions and effusions associated
with tuberculosis from others.
Chierakul et al. [16] studied the value of C-reactive protein
measurement for the differentiation between tuberculous and
malignant pleural effusion. The aim of their study was to
determine the validity of pleural ﬂuid C-reactive protein(CRP) concentrations and/or pleural ﬂuid to serum CRP ratio
for differentiating tuberculous pleuritis (TBP) from malignant
pleural effusion (MPE) in patients presenting with lymphocytic
exudative pleural effusions. Their study was conducted on 161
patients with pleural effusion. Among the 148 patients with
lymphocytic exudative pleural effusions, 55 were diagnosed
with TBP, 60 with MPE, and 33 with non-speciﬁc pleuritis.
Pleural ﬂuid and serum CRP levels were signiﬁcantly higher
in the TBP group than in the MPE group. The ratio of pleural
ﬂuid to serum CRP was signiﬁcantly higher in the TBP group
than in the MPE group. They concluded that in patients pre-
senting with lymphocytic exudative pleural effusion, a simple
marker of raised pleural ﬂuid CRP level may be helpful in dis-
criminating between TBP and MPE.
Pachon et al. [17] determined whether CRP may be a diag-
nostic aid for tuberculosis in lymphocytic pleural effusion.
Their study was carried on 144 patients with, 20 tuberculous
pleurisy, 69 malignant effusion, 38transudative effusion, and
17 other benign effusion. The CRP pleural ﬂuid level was
higher in tuberculous pleurisy than lymphocytic effusion of
other origin.
They concluded that, CRP pleural ﬂuid determination is
useful in diagnostic work up of lymphocytic pleural effusions.
High CRP levels are very suggestive of tuberculous pleurisy
and low CRP levels are with malignant pleural effusion.
In the present study, signiﬁcant positive correlation
between serum and pleural ﬂuid CRP levels was observed
and it was signiﬁcantly higher in para-pneumonic and tubercu-
lous compared to transudative and malignant effusions. This is
attributed to the fact that, higher CRP values found in pleural
ﬂuid in non-malignant effusions probably reﬂect higher degree
of inﬂammation and increased vascular permeability of pleura
in these cases.
These results are in agree with Daniil et al. [15] who studied
the use of pleural ﬂuid C-reactive protein in laboratory diagno-
sis of pleural effusions. The aim of their study to investigate its
usefulness as a marker of bacterial infection in patients with
pleural effusion. There was a correlation between the pleural
and serum C-reactive protein.
They concluded that, higher pleural ﬂuid CRP-levels may
prove to be a practical, accurate and rapid method for differ-
entiating para-pneumonic effusions and effusions associated
with tuberculosis from others.
Sedky et al., [18] also found a highly signiﬁcant difference
between pleural ﬂuid CRP in tuberculous (29.07 ± 9.32)
and malignant (19.30 ± 4.35) effusions. Moreover, serum
CRP was signiﬁcantly higher in tuberculous effusion
(52.24 ± 8.55) compared to malignant one (30.65 ± 5.08).
They concluded that CRP is a useful and cheap marker for
differentiation between tuberculous and malignant pleural
effusion.Conﬂict of interest
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